AIM: To assess the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy subjects of a novel, highly selective, sigma-1 receptor antagonist (S1RA). METHODS: Three randomized, double-blind, placebo-controlled trials evaluated single oral doses (5-500 mg, study 101; 500-800 mg, study 106) and multiple doses (50-400 mg once daily for 8 days, study 102) of S1RA. Safety and tolerability were assessed by adverse event reporting, clinical laboratory, physical examinations, vital signs and electrocardiography, including Holter monitoring. Pharmacodynamic assessments included computerized cognitive testing. Plasma samples were analyzed using validated HPLC-MS/MS methods. RESULTS:One hundred and seventy-five subjects were enrolled. Single and multiple doses were safe and well tolerated, with no serious adverse events. The most common side effects were headache and dizziness. The highest single doses were associated with some mild to moderate transient CNS effects. The maximum tolerated dose was not reached. There were no clinically significant changes in the electrocardiogram (ECG), 24 h Holter monitoring, or in vital signs and laboratory assessments. Subjective CNS pharmacodynamics evaluations showed no relevant differences vs. placebo. Cognitive testing showed no effects on visual memory, executive function, attention or somnolence, while revealing some transient slowing of response for simple reaction time and choice reaction time at 2 h following the administration of higher doses. A fast absorption, rapid distribution and slow elimination were observed (t(max) 0.75-2.0 h, t(1/2) compatible with once a day administration) and steady-state was reached. No gender differences were observed. CONCLUSIONS:S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.
RCT Entities:
AIM: To assess the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy subjects of a novel, highly selective, sigma-1 receptor antagonist (S1RA). METHODS: Three randomized, double-blind, placebo-controlled trials evaluated single oral doses (5-500 mg, study 101; 500-800 mg, study 106) and multiple doses (50-400 mg once daily for 8 days, study 102) of S1RA. Safety and tolerability were assessed by adverse event reporting, clinical laboratory, physical examinations, vital signs and electrocardiography, including Holter monitoring. Pharmacodynamic assessments included computerized cognitive testing. Plasma samples were analyzed using validated HPLC-MS/MS methods. RESULTS: One hundred and seventy-five subjects were enrolled. Single and multiple doses were safe and well tolerated, with no serious adverse events. The most common side effects were headache and dizziness. The highest single doses were associated with some mild to moderate transient CNS effects. The maximum tolerated dose was not reached. There were no clinically significant changes in the electrocardiogram (ECG), 24 h Holter monitoring, or in vital signs and laboratory assessments. Subjective CNS pharmacodynamics evaluations showed no relevant differences vs. placebo. Cognitive testing showed no effects on visual memory, executive function, attention or somnolence, while revealing some transient slowing of response for simple reaction time and choice reaction time at 2 h following the administration of higher doses. A fast absorption, rapid distribution and slow elimination were observed (t(max) 0.75-2.0 h, t(1/2) compatible with once a day administration) and steady-state was reached. No gender differences were observed. CONCLUSIONS: S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.
Authors: L Romero; D Zamanillo; X Nadal; R Sánchez-Arroyos; I Rivera-Arconada; A Dordal; A Montero; A Muro; A Bura; C Segalés; M Laloya; E Hernández; E Portillo-Salido; M Escriche; X Codony; G Encina; J Burgueño; M Merlos; J M Baeyens; J Giraldo; J A López-García; R Maldonado; C R Plata-Salamán; J M Vela Journal: Br J Pharmacol Date: 2012-08 Impact factor: 8.739
Authors: José Luis Díaz; Daniel Zamanillo; Jordi Corbera; José Manuel Baeyens; Rafael Maldonado; Miquel Angel Pericàs; José Miguel Vela; Antoni Torrens Journal: Cent Nerv Syst Agents Med Chem Date: 2009-09
Authors: José Manuel Entrena; Enrique José Cobos; Francisco Rafael Nieto; Cruz Miguel Cendán; Georgia Gris; Esperanza Del Pozo; Daniel Zamanillo; José Manuel Baeyens Journal: Pain Date: 2009-04-17 Impact factor: 6.961
Authors: José M Entrena; Enrique J Cobos; Francisco R Nieto; Cruz M Cendán; José M Baeyens; Esperanza Del Pozo Journal: Psychopharmacology (Berl) Date: 2009-03-27 Impact factor: 4.530
Authors: Beatriz de la Puente; Xavier Nadal; Enrique Portillo-Salido; Ricard Sánchez-Arroyos; Sergio Ovalle; Gabriel Palacios; Asunción Muro; Luz Romero; José Manuel Entrena; José Manuel Baeyens; José Antonio López-García; Rafael Maldonado; Daniel Zamanillo; José Miguel Vela Journal: Pain Date: 2009-06-07 Impact factor: 6.961
Authors: Miguel A Tejada; Angeles Montilla-García; Shane J Cronin; Domagoj Cikes; Cristina Sánchez-Fernández; Rafael González-Cano; M Carmen Ruiz-Cantero; Josef M Penninger; José M Vela; José M Baeyens; Enrique J Cobos Journal: Proc Natl Acad Sci U S A Date: 2017-07-17 Impact factor: 11.205
Authors: Nisha K Ramakrishnan; Anniek K D Visser; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde Journal: Psychopharmacology (Berl) Date: 2014-03-18 Impact factor: 4.530
Authors: Aline A Oliveira; Célio F Lipinski; Estevão B Pereira; Kathia M Honorio; Patrícia R Oliveira; Karen C Weber; Roseli A F Romero; Alexsandro G de Sousa; Albérico B F da Silva Journal: J Mol Model Date: 2017-10-02 Impact factor: 1.810
Authors: José Luis Díaz; Jordi Corbera; Daniel Martínez; Magda Bordas; Cristina Sicre; Rosalia Pascual; Mª José Pretel; Ana Paz Marín; Ana Montero; Albert Dordal; Inés Alvarez; Carmen Almansa Journal: Medchemcomm Date: 2017-04-20 Impact factor: 3.597
Authors: José Luis Díaz; Jordi Corbera; Rosa Cuberes; Montserrat Contijoch; Raquel Enrech; Sandra Yeste; Ana Montero; Albert Dordal; Xavier Monroy; Carmen Almansa Journal: Medchemcomm Date: 2017-04-20 Impact factor: 3.597
Authors: María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Raquel Herrero-Labrador; Ricardo Martínez-Murillo; Manuel Merlos; José Miguel Vela; Javier Garzón Journal: Antioxid Redox Signal Date: 2015-02-18 Impact factor: 8.401